About this trial
This cross-sectional study aims to evaluate the role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as inflammatory markers in patients with Helicobacter pylori-associated gastritis at Assiut University Hospitals.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
- Age 18 years or older
Patients with dyspepsia
Patients undergoing endoscopy and biopsy for H. pylori testing
Willingness to provide informed consent
Disqualifiers
- Hematological diseases
Active infection other than H. pylori
Chronic inflammatory or autoimmune diseases
Malignancy
Trial population
Adult patients with dyspepsia undergoing endoscopy and biopsy for H. pylori testing at Assiut University Hospitals.
Trial design
Case-only
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Neutrophil-to-lymphocyte ratio (NLR) in H. pylori-associated gastritis
Neutrophil-to-lymphocyte ratio calculated from complete blood count in patients with confirmed H. pylori-associated gastritis compared with patients without H. pylori infection.
Secondary outcomes
Platelet-to-lymphocyte ratio (PLR)
Platelet-to-lymphocyte ratio calculated from complete blood count in patients with and without H. pylori infection.
Diagnostic performance of NLR
Sensitivity, specificity, and optimal cutoff value of NLR for predicting H. pylori infection using receiver operating characteristic (ROC) curve analysis.
Diagnostic performance of PLR
Sensitivity, specificity, and optimal cutoff value of PLR for predicting H. pylori infection using ROC curve analysis.
Correlation of NLR and PLR with severity of gastritis
Correlation coefficient between neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) values and the severity grade of gastritis based on endoscopic and/or histopathological findings, using Spearman or Pearson correlation as appropriate.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: